. Author manuscript; available in PMC: 2020 Feb 1.

Published in final edited form as: J Neurooncol. 2019 Jan 14;141(3):479–486. doi: 10.1007/s11060-019-03098-y

Table 1.

Pivotal Studies: Biopsy-Based Diagnostic Measures

Measure	Study 3	Study28	Study 30
	(Primary)	(Primary)	(Recurrent)
PPV	97.8	96.2	96.6
NPV	18.8	24.1	18.8
Sensitivity	70.6	67.7	96.3
Specificity	81.1	79.4	20.0

Study 3: Stummer W. et al. (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7: 392–401

Study 28: Stummer W. et al. (2014) 5-Aminolevulinic acid-derived tumor fluorescence: the diagnostic accuracy of visible fluorescence qualities as corroborated by spectrometry and histology and postoperative imaging. Neurosurgery 74: 310–319; discussion 319–320

Study 30: Nabavi A, Thurm H, Zountsas B, Pietsch T, Lanfermann H, Pichlmeier U, Mehdorn M, Group ALARGS (2009) Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study. Neurosurgery 65: 1070–1076; discussion 1076–1077